DEFA14A: Neumora Therapeutics Faces Nasdaq Delisting Threat Due to Low Stock Price

Neumora Therapeutics is at risk of being delisted from the Nasdaq Global Select Market due to non-compliance with the minimum bid price requirement.

Summary

• Neumora Therapeutics received a notice from Nasdaq on May 14, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.
• The company has until November 10, 2025, to regain compliance by maintaining a closing bid price of $1.00 or higher for at least ten consecutive business days.
• Neumora may apply to transfer to The Nasdaq Capital Market if it doesn't regain compliance by the deadline, needing to meet other listing requirements.
• The company intends to monitor its stock price and is considering a reverse stock split to address the noncompliance.
• Stockholders will vote on a proposal for a reverse stock split at the Annual Meeting on May 28, 2025, with a ratio between 1-for-5 and 1-for-30.
• There is no guarantee that stockholders will approve the reverse stock split or that the company will regain compliance with Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the risk of delisting, but there are potential solutions being considered, such as a reverse stock split.

Positives

• Neumora has the option to regain compliance by November 10, 2025.
• The company can apply to transfer to The Nasdaq Capital Market if it fails to meet the initial deadline.
• A reverse stock split is being considered as a potential solution to increase the stock price.

Negatives

• Neumora is currently not in compliance with Nasdaq's minimum bid price requirement.
• There is a risk of delisting from The Nasdaq Global Select Market if compliance is not regained.
• Stockholder approval for the reverse stock split is not guaranteed.

Risks

• Failure to regain compliance with the minimum bid price requirement could lead to delisting from Nasdaq.
• Stockholders may not approve the proposed reverse stock split.
• Even with a reverse stock split, there is no guarantee that the company will meet Nasdaq's listing criteria.

Future Outlook

The company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement, including effecting a reverse stock split of its common stock.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement, including effecting a reverse stock split of its common stock.

Industry Context

Delisting notices are not uncommon, especially for smaller biotech companies facing financial pressures or clinical trial setbacks. Many companies in similar situations consider reverse stock splits or explore strategic alternatives.

Comparison to Industry Standards

• Many biotech companies facing similar stock price challenges have implemented reverse stock splits to maintain Nasdaq listing compliance.
• Other companies have explored mergers, acquisitions, or private placements to improve their financial position and stock price.
• The success of a reverse stock split in maintaining compliance depends on various factors, including market conditions and investor sentiment.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial situation.
• The company's ability to raise capital and fund its operations could be affected.

Next Steps

• Neumora will monitor its stock price.
• Neumora will consider options to resolve the noncompliance.
• Stockholders will vote on the reverse stock split proposal on May 28, 2025.
• Neumora may apply to transfer to The Nasdaq Capital Market if it doesn't regain compliance by November 10, 2025.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, reverse stock split, compliance, Neumora Therapeutics, stock price